Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/s41408-020-0281-x.pdf
Reference15 articles.
1. Keiffer, G. & Palmisiano, N. Acute myeloid leukemia: update on upfront therapy in elderly patients. Curr. Oncol. Rep. 21, 71 (2019).
2. Ferrara, F., Lessi, F., Vitagliano, O., Birkenghi, E. & Rossi, G. Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers 11, E224 (2019).
3. DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 133, 7–17 (2019).
4. Wei, A. H. et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J. Clin. Oncol. 37, 1277–1284 (2019).
5. Winters, A. C. et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 3, 2911–2919 (2019).
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review;Leukemia Research;2023-10
2. Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review;Cancers;2023-02-21
3. Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling;PLOS ONE;2022-04-22
4. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience;Leukemia Research;2022-03
5. Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerations;Expert Review of Clinical Pharmacology;2021-12-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3